PMID- 32757734
OWN - NLM
STAT- MEDLINE
DCOM- 20220113
LR  - 20220531
IS  - 1532-4311 (Electronic)
IS  - 0882-0139 (Linking)
VI  - 50
IP  - 8
DP  - 2021 Nov
TI  - Upregulation of microRNA-155 Enhanced Migration and Function of Dendritic Cells 
      in Three-dimensional Breast Cancer Microenvironment.
PG  - 1058-1071
LID - 10.1080/08820139.2020.1801721 [doi]
AB  - Background: Dendritic cells (DCs) play an essential role in the induction and 
      regulation of immune responses, including the activation of effector T 
      lymphocytes for the eradication of cancers. However, the tumor microenvironment 
      (TME) often leads to DCs dysfunction due to their immature state. MicroRNA-155 
      (miR-155) has emerged as a typical multifunctional gene regulator associated with 
      immune system development and immune cell activation and differentiation.Methods: 
      In this study, a three-dimensional TME model that closely mimics the 
      microenvironment of breast cancer was prepared. MiR-155 overexpression and 
      control vectors were constructed using lentivirus. The relative expression of 
      miR-155 was determined by qRT-PCR. Cell viability, antigen uptake and cell 
      surface marker expression were analyzed by live-dead staining and flow cytometry. 
      The migration ability of bone marrow-derived DCs (BMDCs) was qualified by 
      transwell assay. A mixed lymphocyte culture assay was used to assess T 
      cell-specific proliferation. Cytokine levels were determined by ELISA.Results: We 
      found that the expression of miR-155 in DCs was inhibited by the TME. 
      Furthermore, upregulation of miR-155 enhanced the migration ability, uptake of 
      antigen and elevated the expression of the mature DCs markers CD80 and MHCII. 
      More importantly, overexpression of miR-155 in DCs significantly induced T cell 
      proliferation and IFN-gamma and IL-2 secretion.Conclusion: MiR-155 is a potential 
      molecular regulator that may improve the efficacy of DCs-based tumor 
      immunotherapy.
FAU - Yang, Pengxiang
AU  - Yang P
AD  - Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, 
      Co-innovation Center of Neuroregeneration, Nantong University, Nantong, China.
AD  - Institute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical 
      Science, Harbin Medical University, Harbin, China.
FAU - Cao, Xingjian
AU  - Cao X
AD  - Medical Research Center, Affiliated Hospital 2 of Nantong University, the First 
      People's Hospital of Nantong, Nantong, China.
FAU - Cai, Huilong
AU  - Cai H
AD  - Institute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical 
      Science, Harbin Medical University, Harbin, China.
FAU - Chen, Xiang
AU  - Chen X
AD  - Medical Research Center, Affiliated Hospital 2 of Nantong University, the First 
      People's Hospital of Nantong, Nantong, China.
FAU - Zhu, Yihua
AU  - Zhu Y
AD  - Medical Research Center, Affiliated Hospital 2 of Nantong University, the First 
      People's Hospital of Nantong, Nantong, China.
FAU - Yang, Yue
AU  - Yang Y
AD  - Institute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical 
      Science, Harbin Medical University, Harbin, China.
FAU - An, Weiwei
AU  - An W
AD  - Institute of Cancer Prevention and Treatment, Heilongjiang Academy of Medical 
      Science, Harbin Medical University, Harbin, China.
FAU - Jie, Jing
AU  - Jie J
AD  - Medical Research Center, Affiliated Hospital 2 of Nantong University, the First 
      People's Hospital of Nantong, Nantong, China.
LA  - eng
PT  - Journal Article
DEP - 20200805
PL  - England
TA  - Immunol Invest
JT  - Immunological investigations
JID - 8504629
RN  - 0 (MIRN155 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - *Breast Neoplasms/genetics
MH  - Cells, Cultured
MH  - Dendritic Cells
MH  - Female
MH  - Humans
MH  - *MicroRNAs/genetics
MH  - Tumor Microenvironment
MH  - Up-Regulation
OTO - NOTNLM
OT  - T cells activation
OT  - Three-dimensional culture
OT  - dendritic cells
OT  - microRNA-155
OT  - tumor microenvironment
EDAT- 2020/08/08 06:00
MHDA- 2022/01/14 06:00
CRDT- 2020/08/08 06:00
PHST- 2020/08/08 06:00 [pubmed]
PHST- 2022/01/14 06:00 [medline]
PHST- 2020/08/08 06:00 [entrez]
AID - 10.1080/08820139.2020.1801721 [doi]
PST - ppublish
SO  - Immunol Invest. 2021 Nov;50(8):1058-1071. doi: 10.1080/08820139.2020.1801721. 
      Epub 2020 Aug 5.